 |
Antineo |
| Your oncology NEOsletter |
| Monthly news from oncology science and industries — by Antineo, your preclinical partner in oncology |
| October 2026 issue |
|
|
This month in oncology, we have seen 28 investment deals signed, 6 FDA approvals, publications in Nature Reviews & Lancet and still 12 upcoming conferences and congresses.
|
|
|
|
|
|
| Matchpoint Therapeutics |
2026-10-07 |
Matchpoint closes $150M Series B to advance oral T cell modulator MPT-062 for autoimmune diseases.
Source: Bio-IT World →
|
|
| Series D · $135M |
|
Switzerland |
Nouscom closes oversubscribed €120M Series D to fund pivotal cancer interception trial in Lynch Syndrome.
Source: GlobeNewswire →
|
|
Show all 28
| Soufflé Therapeutics |
2026-10-13 |
Soufflé raises $135M Series B to advance extra-hepatic RNA therapies for FSHD and heart failure into the clinic.
Source: The Pharma Letter →
|
|
| Iambic Therapeutics |
2026-10-15 |
Iambic Therapeutics raises $150M in IPO to fuel clinical development of its AI-driven oncology pipeline.
Source: Fierce Biotech →
|
|
|
|
| Estuary Biotherapeutics |
2026-10-16 |
Estuary launches with $93M Series A to develop AAV gene therapies for inherited kidney disease ADPKD.
Source: BioPharm International →
|
|
|
|
|
KymaThera raises $80M Series B to develop PI3Kα inhibitor K-1728 for breast cancer and vascular malformations.
Source: Endpoints News →
|
|
|
|
|
|
| Prolific Machines |
2026-10-14 |
Prolific Machines raises $50M Series B2 to scale its optogenetics-enabled biologics manufacturing platform.
Source: Bio-IT World →
|
|
| Series C · $48M |
|
United Kingdom |
Microbiotica raises £36M ($48M) Series C to advance microbiome therapy MB310 for ulcerative colitis into Phase 2.
Source: GlobeNewswire →
|
|
| Sensible Biotechnologies |
2026-10-06 |
Sensible Biotechnologies secures $47M Series A and non-dilutive funding to scale its cell-based mRNA manufacturing platform.
Source: Endpoints News →
|
|
| Retension Pharmaceuticals |
2026-10-09 |
Retension Pharmaceuticals raises $45M in upsized IPO to advance oral PDE-5 inhibitor RTN-001 for hypertension.
Source: PharmExec →
|
|
| Altay Therapeutics |
2026-10-14 |
Altay Therapeutics closes $37M Series A to advance oral DUX4 inhibitor DX5057 for FSHD into Phase 1/2 trials.
Source: FinSMEs →
|
|
| Epicrispr Biotechnologies |
2026-10-19 |
Epicrispr Biotechnologies awarded $8M CIRM grant to advance EPI-321 epigenetic therapy for FSHD in first-in-human trials.
Source: FinSMEs →
|
|
|
|
| Sinopia Biosciences |
2026-10-20 |
Sinopia Biosciences awarded $2.5M NIH SBIR Phase II grant to advance AI metabolomics drug discovery platform.
Source: BioSpace / Business Wire →
|
|
|
|
|
Biotia raises $9M in follow-on financing to scale its infectious disease molecular diagnostics platform.
Source: NewMarketPitch →
|
|
| Series E · $237M |
|
USA (New York) |
AI-driven drug development startup raised $237M Series E led by Bristol-Myers Squibb.
Source: Crunchbase →
|
|
| Star Therapeutics |
2026-10-17 |
| Venture Round · $200M |
|
USA (South San Francisco, CA) |
Drug developer raised $200M led by OrbiMed and Janus Henderson Investors.
Source: Crunchbase →
|
|
| Soufflé Therapeutics |
2026-10-10 |
| Series B · $135M |
|
USA (Boston, MA) |
RNA therapy developer raised $135M Series B led by Juvia Group.
Source: Crunchbase →
|
|
| Estuary Biotherapeutics |
2026-10-10 |
| Series A · $103M |
|
USA (Menlo Park, CA) |
Genetic medicines developer for kidney diseases launched with $103M Series A led by RA Capital.
Source: Crunchbase →
|
|
|
|
|
|
|
|
|
|
| FDA approves talazoparib (Talzenna) with enzalutamide for metastatic prostate cancer with HRR gene mutations |
| October 26, 2026 · FDA |
| Read source → |
|
|
| FDA grants accelerated approval to dostarlimab (Jemperli) for locally advanced MSI-H/dMMR rectal cancer |
| October 19, 2026 · FDA |
| Read source → |
|
|
| FDA grants traditional approval to pembrolizumab for unresectable or metastatic TMB-H solid tumors |
| October 16, 2026 · FDA |
| Read source → |
|
|
Show all 7
| FDA approves expanded indication for Anktiva in BCG-unresponsive non-muscle invasive bladder cancer |
| October 14, 2026 · FDA |
| Read source → |
|
|
| FDA approves atezolizumab (Tecentriq) with chemotherapy for Stage III dMMR colon cancer |
| October 8, 2026 · FDA |
| Read source → |
|
|
| FDA approves tucatinib (Tukysa) with trastuzumab and pertuzumab as maintenance for HER2-positive breast cancer |
| October 7, 2026 · FDA |
| Read source → |
|
|
| FDA approves pirtobrutinib (Jaypirca) for previously untreated CLL/SLL |
| October 2, 2026 · FDA |
| Read source → |
|
|
|
| Upcoming Conferences & Events |
|
|
EACR Conference: Chromosomes in Crisis
November 3-5, 2026 · Berlin, Germany
More info →
|
|
|
SITC Annual Meeting 2026
November 4-8, 2026 · Phoenix, AZ, USA
More info →
|
|
|
Chemotherapy Foundation Symposium
November 11-13, 2026 · New York, NY, USA
More info →
|
|
Show all 12
|
Excellence in Oncology Care (EIOC 2026)
November 13-14, 2026 (virtual day November 15) · Dubai, UAE
More info →
|
|
|
ESMO AI and Digital Oncology Congress 2026
November 16-18, 2026 · Berlin, Germany
More info →
|
|
|
International Kidney Cancer Symposium (IKCS) North America
November 19-21, 2026 · Dallas, TX, USA
More info →
|
|
|
Society of Urologic Oncology Annual Meeting
December 1-4, 2026 · San Diego, CA, USA
More info →
|
|
|
RENALC-BLADDR-PROSCA 2026 Hybrid Global Forum
December 2-5, 2026 · Amsterdam, Netherlands
More info →
|
|
|
ESMO Asia Congress 2026
December 4-6, 2026 · Singapore
More info →
|
|
|
San Antonio Breast Cancer Symposium (SABCS)
December 8-11, 2026 · San Antonio, TX, USA
More info →
|
|
|
ASH Annual Meeting & Exposition
December 12-15, 2026 · New Orleans, LA, USA
More info →
|
|
|
ESMO Immuno-Oncology Congress 2026
December 14-16, 2026 · London, UK (online option available)
More info →
|
|
|
|
|
Real-world efficacy and safety of trastuzumab emtansine biosimilar (UJVIRA<sup>®</sup>) in early and metastatic HER2-positive breast cancer: a multicenter pooled retrospective analysis from India.
Breast cancer research and treatment · 2026-10-28 · Mahajan A et al.
Purpose Trastuzumab-emtansine (T-DM1), an antibody drug conjugate, is approved in the adjuvant (residual disease post-neoadjuvant chemotherapy) and metastatic settings…
Read on PubMed →
|
|
|
Sacituzumab tirumotecan versus treatment of physician's choice in previously treated endometrial cancer (TroFuse-005/ENGOT-en23/GOG-3095): a randomised, open-label, phase 3 trial.
Lancet (London, England) · 2026-10-26 · Lorusso D et al.
Background Therapeutic options for patients with endometrial cancer who progress after platinum-based chemotherapy and immunotherapy are scarce, and prognosis is poor.
Read on PubMed →
|
|
|
A Living Multi-Omics PDX Biobank of High-Risk Sarcomas Reveals ecDNA-Driven Oncogene Amplification in Osteosarcoma and Enables Preclinical Precision Oncology.
Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026-10-12 · Zhao W et al.
Sarcomas are rare, genomically heterogeneous malignancies for which prognosis has remained poor and largely unchanged over recent decades.
Read on PubMed →
|
|
Show all 6
|
A modular framework for antibody-drug conjugate biomarkers.
Nature reviews. Clinical oncology · 2026-10-09 · Liu J et al.
The availability of approved antibody-drug conjugates (ADCs) has rapidly expanded across oncology indications, yet biomarker development remains dominated by…
Read on PubMed →
|
|
|
Right-sizing treatment for HER2-positive breast cancer: evolving algorithms across the disease continuum.
Nature reviews. Clinical oncology · 2026-10-08 · Tarantino P et al.
Human epidermal growth factor receptor 2 (HER2)-positive breast cancer has undergone one of the most profound therapeutic transformations in oncology.
Read on PubMed →
|
|
|
Redefining breast cancer treatment by precision oncology: the clinical impact of sacituzumab govitecan.
Expert opinion on biological therapy · 2026-10-07 · Di Lauro V et al.
Introduction Trophoblast cell-surface antigen-2 (Trop-2) is overexpressed in most breast cancers, including about 90% of triple-negative breast cancers (TNBC) and more…
Read on PubMed →
|
|
|
| Antineo |
| You are receiving this email because you are subscribed to Your oncology NEOsletter. Unsubscribe |
|
|
